Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ed Silverman
As controversy continues over pharmaceutical pricing, more drugmakers are eyeing deals that peg health plan cost to outcomes to boost volume and win formulary placement. But these deals are challenging to construct and to date there is little evidence that they reduce costs for patients.
California's Proposition 61 and a number of other state-led measures to control drug prices failed to gain traction in 2016. But states are likely to remain a battleground in the war against costs in a pharma-friendly Trump administration.
A look at recent state legislation designed to require prescription drug cost and price transparency from prescription drug manufacturers. Data from the National Conference of State Legislatures.
Bio-Path Holdings is trying to become the next company to make it big with antisense drugs. Recently, the Houston-based biotech released data showing its lead compound, which is known as BP-1001, may hold promise in treating advanced acute myeloid leukemia, or AML.
The RNA drugmaker raised its $66 million Series B just as the markets started to go south.
In June, Axovant Sciences Ltd. launched an IPO in which its stock almost doubled on the first day of trading and its valuation approached a frothy $3 billion. And this startling performance was attributed to just one asset – an experimental compound for Alzheimer’s disease.